Condition: Acute Respiratory Distress Syndrome · Adult Respiratory Distress Syndrome · Acute Lung Injury · Sponsor: Implicit Bioscience
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.
This description comes directly from the study's public registry record.
Linzee Mabrey, MD, MSc · (206) 897-5051 · mflinzee@uw.edu
Always discuss trial participation with your own doctor first.
| Harborview Medical Center | Seattle, Washington, United States | Recruiting |
| University of Washington | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06513949